Brief: Hbm Holdings Enters Global Strategic Collaboration And License Agreement With Bristol Myers Squibb
17/12/2025 01:14
Dec 17 (Reuters) - Hbm Holdings Ltd 2142.HK: ENTERING INTO GLOBAL STRATEGIC COLLABORATION AND LICENSE AGREEMENT WITH BRISTOL MYERS SQUIBB COULD RECEIVE PAYMENTS TOTALING $90 MILLION & DEVELOPMENT AND COMMERCIAL MILESTONES OF UP TO $1,035 MILLION UNDER DEAL UNDER DEAL, CO TO COLLABORATE TO ADVANCE AND ACCELERATE MULTI-SPECIFIC ANTIBODY DISCOVERY PROGRAMS Further company coverage: 2142.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on HBM Holdings
See all newsBrief: HBM Holdings Says NMPA Approves Batoclimab Injection For Generalized Myasthenia Gravis
HBM climbs on development of AI biology foundation model
Brief: HBM Holdings' Unit Develops World's First Language Model For Fully Human Heavy-Chain-Only Antibodies
Brief: Hbm Holdings Says Solstice Oncology Launches Series A Financing Round
HK-listed HBM climbs on initiating next phase of asthma drug study